These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33722933)

  • 21. Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders: A 14-Year Real-Life Experience.
    Kim SH; Park NY; Kim KH; Hyun JW; Kim HJ
    Neurol Neuroimmunol Neuroinflamm; 2022 Sep; 9(5):. PubMed ID: 35853752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
    Md Yusof MY; Vital EM; McElvenny DM; Hensor EMA; Das S; Dass S; Rawstron AC; Buch MH; Emery P; Savic S
    Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis.
    Liu H; Zhou H; Wang J; Sun M; Teng D; Song H; Xu Q; Wei S
    J Neurol Sci; 2019 Jan; 396():225-231. PubMed ID: 30522039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
    Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study.
    Stiebel-Kalish H; Lotan I; Brody J; Chodick G; Bialer O; Marignier R; Bach M; Hellmann MA
    PLoS One; 2017; 12(1):e0170847. PubMed ID: 28125740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.
    Ramanathan S; Prelog K; Barnes EH; Tantsis EM; Reddel SW; Henderson AP; Vucic S; Gorman MP; Benson LA; Alper G; Riney CJ; Barnett M; Parratt JD; Hardy TA; Leventer RJ; Merheb V; Nosadini M; Fung VS; Brilot F; Dale RC
    Mult Scler; 2016 Apr; 22(4):470-82. PubMed ID: 26163068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study.
    Wade SD; Kyttaris VC
    Rheumatol Int; 2021 Jun; 41(6):1115-1124. PubMed ID: 33811499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.
    Jurynczyk M; Geraldes R; Probert F; Woodhall MR; Waters P; Tackley G; DeLuca G; Chandratre S; Leite MI; Vincent A; Palace J
    Brain; 2017 Mar; 140(3):617-627. PubMed ID: 28364548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
    Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M
    Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with fatigue in CNS inflammatory diseases with AQP4 and MOG antibodies.
    Yeo T; Dos Passos GR; Muhammed L; Everett R; Reeve S; Messina S; Probert F; Leite MI; Palace J
    Ann Clin Transl Neurol; 2020 Mar; 7(3):375-383. PubMed ID: 32187851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients.
    Hamid SHM; Whittam D; Mutch K; Linaker S; Solomon T; Das K; Bhojak M; Jacob A
    J Neurol; 2017 Oct; 264(10):2088-2094. PubMed ID: 28840314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.
    Dubey D; Pittock SJ; Krecke KN; Morris PP; Sechi E; Zalewski NL; Weinshenker BG; Shosha E; Lucchinetti CF; Fryer JP; Lopez-Chiriboga AS; Chen JC; Jitprapaikulsan J; McKeon A; Gadoth A; Keegan BM; Tillema JM; Naddaf E; Patterson MC; Messacar K; Tyler KL; Flanagan EP
    JAMA Neurol; 2019 Mar; 76(3):301-309. PubMed ID: 30575890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the effects of rituximab versus other immunotherapies for MOG-IgG-associated central nervous system demyelination: A meta-analysis.
    Bai P; Zhang M; Yuan J; Zhu R; Li N
    Mult Scler Relat Disord; 2021 Aug; 53():103044. PubMed ID: 34091176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity.
    Chien C; Scheel M; Schmitz-Hübsch T; Borisow N; Ruprecht K; Bellmann-Strobl J; Paul F; Brandt AU
    Mult Scler; 2019 Dec; 25(14):1926-1936. PubMed ID: 30475082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases.
    Mader S; Kümpfel T; Meinl E
    Curr Opin Neurol; 2020 Jun; 33(3):362-371. PubMed ID: 32304439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.
    Cobo-Calvo A; Ruiz A; Maillart E; Audoin B; Zephir H; Bourre B; Ciron J; Collongues N; Brassat D; Cotton F; Papeix C; Durand-Dubief F; Laplaud D; Deschamps R; Cohen M; Biotti D; Ayrignac X; Tilikete C; Thouvenot E; Brochet B; Dulau C; Moreau T; Tourbah A; Lebranchu P; Michel L; Lebrun-Frenay C; Montcuquet A; Mathey G; Debouverie M; Pelletier J; Labauge P; Derache N; Coustans M; Rollot F; De Seze J; Vukusic S; Marignier R;
    Neurology; 2018 May; 90(21):e1858-e1869. PubMed ID: 29695592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of magnetic resonance imaging characteristics in Chinese patients with myelin oligodendrocyte glycoprotein antibody associated disorders].
    Liu CX; Chen C; Zhong XN; Wang YG; Yang Y; Li R; Sun XB; Fang L; Peng LS; Qiu W
    Zhonghua Yi Xue Za Zhi; 2020 Feb; 100(5):328-333. PubMed ID: 32074774
    [No Abstract]   [Full Text] [Related]  

  • 38. Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes.
    Duignan S; Wright S; Rossor T; Cazabon J; Gilmour K; Ciccarelli O; Wassmer E; Lim M; Hemingway C; Hacohen Y
    Dev Med Child Neurol; 2018 Sep; 60(9):958-962. PubMed ID: 29468668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
    Du Q; Shi Z; Chen H; Zhang Y; Wang J; Qiu Y; Zhao Z; Zhang Q; Zhou H
    J Neuroimmunol; 2021 Apr; 353():577494. PubMed ID: 33515897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypogammaglobulinemia and bacterial infections following pediatric post-transplant lymphoproliferative disorder in the rituximab era.
    Chiou FK; Beath SV; Patel M; Gupte GL
    Pediatr Transplant; 2019 Sep; 23(6):e13519. PubMed ID: 31209964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.